Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Brian Birchler sold 680 shares of the stock in a transaction dated Wednesday, April 16th. The shares were sold at an average price of $28.37, for a total value of $19,291.60. Following the transaction, the executive vice president now directly owns 56,660 shares in the company, valued at approximately $1,607,444.20. This represents a 1.19 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Ionis Pharmaceuticals Price Performance
NASDAQ:IONS opened at $28.40 on Friday. The firm has a market cap of $4.51 billion, a PE ratio of -9.34 and a beta of 0.29. The company's 50-day moving average price is $30.93 and its two-hundred day moving average price is $34.31. The company has a quick ratio of 8.82, a current ratio of 8.47 and a debt-to-equity ratio of 2.12. Ionis Pharmaceuticals, Inc. has a 12 month low of $23.95 and a 12 month high of $52.34.
Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The company reported ($0.66) EPS for the quarter, topping analysts' consensus estimates of ($1.12) by $0.46. The business had revenue of $227.00 million for the quarter, compared to analyst estimates of $140.97 million. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. Ionis Pharmaceuticals's revenue for the quarter was down 30.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.12 EPS. On average, equities analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of analysts have recently weighed in on IONS shares. Needham & Company LLC restated a "buy" rating and issued a $60.00 price objective on shares of Ionis Pharmaceuticals in a research note on Tuesday. Redburn Atlantic began coverage on Ionis Pharmaceuticals in a research note on Monday, March 31st. They issued a "neutral" rating and a $39.00 price objective on the stock. Citigroup decreased their target price on Ionis Pharmaceuticals from $67.00 to $64.00 and set a "buy" rating for the company in a research note on Thursday, February 20th. Royal Bank of Canada reissued an "outperform" rating and issued a $70.00 price objective on shares of Ionis Pharmaceuticals in a research report on Thursday, February 20th. Finally, Guggenheim reiterated a "buy" rating on shares of Ionis Pharmaceuticals in a research note on Thursday, April 3rd. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $56.72.
Check Out Our Latest Report on Ionis Pharmaceuticals
Institutional Investors Weigh In On Ionis Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in shares of Ionis Pharmaceuticals by 9.4% in the fourth quarter. Vanguard Group Inc. now owns 16,472,539 shares of the company's stock valued at $575,880,000 after purchasing an additional 1,416,781 shares in the last quarter. Capital World Investors raised its position in shares of Ionis Pharmaceuticals by 46.5% during the fourth quarter. Capital World Investors now owns 11,465,413 shares of the company's stock worth $400,831,000 after acquiring an additional 3,637,041 shares during the last quarter. Orbimed Advisors LLC lifted its stake in shares of Ionis Pharmaceuticals by 21.2% during the fourth quarter. Orbimed Advisors LLC now owns 2,817,347 shares of the company's stock valued at $98,494,000 after acquiring an additional 492,900 shares during the period. Geode Capital Management LLC boosted its holdings in Ionis Pharmaceuticals by 0.7% in the fourth quarter. Geode Capital Management LLC now owns 2,687,248 shares of the company's stock valued at $93,976,000 after acquiring an additional 18,890 shares during the last quarter. Finally, Norges Bank acquired a new stake in Ionis Pharmaceuticals in the fourth quarter worth about $59,948,000. Institutional investors and hedge funds own 93.86% of the company's stock.
About Ionis Pharmaceuticals
(
Get Free Report)
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
